Stay updated on GeneNews LimitedPress Releases
Sign up to get notified when there's something new on the GeneNews LimitedPress Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FA5duhkVTUgxlbGDmiDW355Hs8dA.uncropped.jpg&w=3840&q=75)
Latest updates to the GeneNews LimitedPress Releases page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedDifference6%
- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoNo Change Detected
- Check46 days agoChange DetectedThe website now includes new data for Genentech's Susvimo demonstrating sustained efficacy in two serious diabetic eye conditions, which is likely to be of interest to users monitoring updates on the website.SummaryDifference7%
- Check47 days agoChange DetectedThe website now includes information about Genentech’s Vabysmo showing extended durability, continued efficacy, and a consistent safety profile in a long-term study on Diabetic Macular Edema (DME), while the previous information about FDA approving Genentech's Alecensa as the first adjuvant treatment for ALK-Positive Early-Stage Lung Cancer has been removed.SummaryDifference8%
- Check48 days agoChange DetectedGenentech announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity, a significant development compared to the previous data on Ocrevus for MS patients.SummaryDifference10%
- Check54 days agoChange DetectedThe website has made changes to its privacy choices.SummaryDifference0.6%
- Check56 days agoChange DetectedGenentech is reintroducing Susvimo for people with Wet Age-Related Macular Degeneration, marking a significant update on the website.SummaryDifference8%
Stay in the know with updates to GeneNews LimitedPress Releases
Enter your email address, and we'll notify you when there's something new on the GeneNews LimitedPress Releases page.